Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...
Rheumatology Advisor8h
Inflammatory Arthropathy Risk Increased in Patients With Hidradenitis Suppurativa
Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.
Medscape2d
Deucravacitinib Meets Endpoints in Phase 3 PsA Trial
Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...
Medscape3d
Metabolic Syndrome and Radiographic Damage in Psoriatic Arthritis: Is There a Link?
Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...
Fierce Pharma4d
Trial results enhance Bristol Myers' bid for Sotyktu in psoriatic arthritis
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Managed Healthcare Executive1d
Stelara Biosimilar Steqeyma Launches at 85% Discount
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
Business Wire2d
Celltrion's Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...
DelveInsight Business Research, LLP: Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...